Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Gbathaton Aug 07, 2021 10:38pm
179 Views
Post# 33669005

kaplan poster

kaplan posterhttps://promisneurosciences.com/wp-content/uploads/2021/08/Kaplan-AAIC2021-Poster-55254.pdf

I thought this poster had some interesting data.  The selectivity data for PMN310 continued to look impressive, and the other two antibodies also looked pretty good.

The A-syn data for aggregation (lower graph) looked really compelling.  The PMN310 data, not so much, but that does not rule out the general benefit of toxic amyloid beta binding and clearance. It just indicates that the amyloid beta aggregation pathway might involve more than just the site targeted by PMN310. 

I need to read up on the toxicity mechanisms to learn more, but overall, the poster looked pretty solid to me.  Well done PMN.
<< Previous
Bullboard Posts
Next >>